戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  therapy and it is also used clinically as a thrombolytic agent.
2 sue plasminogen activator, is an alternative thrombolytic agent.
3 ffinity obviates continuous infusion of this thrombolytic agent.
4 cing infarct size in patients treated with a thrombolytic agent.
5 py for acute ischemic stroke is the use of a thrombolytic agent.
6  in ischemia, independent of its effect as a thrombolytic agent.
7 PA) is a highly fibrin-specific single-bolus thrombolytic agent.
8 omy without co-treatment with an intravenous thrombolytic agent.
9 swered questions remain regarding the use of thrombolytic agents.
10 inogen activator are the currently available thrombolytic agents.
11 nimizes the duration of systemic exposure to thrombolytic agents.
12 tra-arterial thrombolysis, and trials of new thrombolytic agents.
13 d antiplatelet therapies in combination with thrombolytic agents.
14 congestive heart failure, who first received thrombolytic agents.
15 tients with myocardial infarction (MI) given thrombolytic agents.
16  be observed in 10 minutes without exogenous thrombolytic agents.
17 hic potential complication of treatment with thrombolytic agents.
18 te the utility of this assay as a screen for thrombolytic agents, a 14-amino-acid PAI-1-inhibitory pe
19 myocardial infarction treated initially with thrombolytic agents-a clinical application previously un
20  medications, including medications (such as thrombolytic agents and beta-blockers) that are associat
21                                   The use of thrombolytic agents and captopril had no significant eff
22 intra-arterial), intra-arterial injection of thrombolytic agents and hyaluronidase, anterior chamber
23                                   The use of thrombolytic agents and invasive treatment plans decline
24 , including intra-arterial administration of thrombolytic agents and mechanical interventions, show p
25 outcomes of patients with OTPHV treated with thrombolytic agents and with surgery since 1996.
26 F or both), time of VT/VF occurrence, use of thrombolytic agents, and eventual outcome are unclear.
27                             New devices, new thrombolytic agents, and new antithrombotic agents are c
28 rlier treatment, the use of third-generation thrombolytic agents, and the use of primary angioplasty.
29 enting; more potent and more fibrin-specific thrombolytic agents; and new antithrombotic and antiplat
30 clinical trials have investigated the use of thrombolytic agents, anticoagulants, antiplatelet drugs
31     Tissue plasminogen activator is the only thrombolytic agent approved in the United States for tre
32                                              Thrombolytic agents, aspirin, beta-blockers, and angiote
33 learest indication for the administration of thrombolytic agents, but patients with acute pulmonary e
34 h Gd-complexes (Gd-lip) co-encapsulated with thrombolytic agents can serve both for imaging and treat
35                        In the absence of any thrombolytic agent, clots fully retracted within 2.5 h a
36        There was no benefit when intravenous thrombolytic agent co-treatment was used.
37 % of patients aged 75 to 84 years received a thrombolytic agent compared with 21.4% between 1 June 19
38 atients younger than age 55 years received a thrombolytic agent during hospitalization for acute myoc
39 ctive treatment option in conjunction with a thrombolytic agent for stroke patients.
40 teplase is being evaluated as an alternative thrombolytic agent for the treatment of acute ischemic s
41     Alteplase is currently the only approved thrombolytic agent for treatment of acute ischaemic stro
42 asminogen activator (rh-tPA) is an important thrombolytic agent for treatment of acute ischemic strok
43 and IPF2alpha-I levels in patients receiving thrombolytic agents for acute MI.
44 y be justified in severe cases, the role for thrombolytic agents for less symptomatic deep venous thr
45 rest is burgeoning in the development of new thrombolytic agents for systemic reperfusion with an imp
46 TAFIa could enhance the efficacy of existing thrombolytic agents for the treatment of acute myocardia
47 ome after myocardial infarction treated with thrombolytic agents from a large international cohort.
48 nting, glycoprotein IIb/IIIa inhibitors plus thrombolytic agents, glycoprotein IIb/IIIa inhibitors pl
49 al, an appropriate dose of this single-bolus thrombolytic agent has been identified for phase III tes
50 te ST segment elevation MI, new single-bolus thrombolytic agents have been unable to break the "throm
51                             Although current thrombolytic agents have proven their clinical benefit,
52 uture directions for a safer use of tPA as a thrombolytic agent in the setting of acute ischemic stro
53     Patients meeting ECG criteria were given thrombolytic agents in 49% of cases, but age, comorbidit
54  must be excluded prior to administration of thrombolytic agents in acute stroke.
55                                          All thrombolytic agents in current clinical usage are plasmi
56  as well as local intra-arterial delivery of thrombolytic agents in patients with acute stroke, are t
57  helped avoid the risks from angiography and thrombolytic agents in some or spurred the judicious use
58 ubbles not only enhance the effectiveness of thrombolytic agents in the presence of ultrasound but ma
59 py may be a non-invasive safe alternative to thrombolytic agents in treating thrombotic CVC occlusion
60 nergistic effect on thrombus disruption with thrombolytic agents in vitro.
61                                              Thrombolytic agents (including tissue plasminogen activa
62                                              Thrombolytic agents, including tenecteplase, are general
63 placement and to allow administration of the thrombolytic agent into the core of the haematoma via a
64                    Further study of this new thrombolytic agent is ongoing.
65            Streptokinase (SK), a widely used thrombolytic agent, is an efficient activator of human P
66 TNK-tPA, a fibrin specific second generation thrombolytic agent, is effective in reducing ischemic vo
67                                        Newer thrombolytic agents may have advantages, but are less we
68                   Our findings indicate that thrombolytic agents may have therapeutic value in the tr
69                              The effect of a thrombolytic agent on biochemical bond degradation was m
70 theterization was performed more often after thrombolytic agents (OR 1.85, 95% CI 0.97 to 3.54), but
71 s older age and therapy with anticoagulants, thrombolytic agents, or captopril affect long-term rates
72 minogen activator (TPA) with a direct-acting thrombolytic agent, plasmin, in an animal model of fibri
73                                   The use of thrombolytic agents (plasminogen activators) in the earl
74 VWF) that blocks VWF binding to GPIb, of the thrombolytic agent recombinant tissue plasminogen activa
75                            In addition, both thrombolytic agents reduced cerebral lesion volume (dete
76              In contrast, Microlyse, a novel thrombolytic agent, requires von Willebrand factor (VWF)
77                    Finally, we show that the thrombolytic agent streptokinase has therapeutic value f
78 f important virulence factors, including the thrombolytic agent streptokinase, the protease inhibitor
79 ich regulates the expression of pili and the thrombolytic agent streptokinase.
80  urokinase-type plasminogen activator or the thrombolytic agent streptokinase.
81  as in clots that have been treated with the thrombolytic agents streptokinase and alteplase.
82 lacing of the thrombus with a fibrin-binding thrombolytic agent such as alteplase is an alternative t
83 parin, oral anticoagulants, antibiotics, and thrombolytic agents such as urokinase and tissue plasmin
84 rial and requires a more effective and safer thrombolytic agent than those currently available.
85 plase has emerged as a potential alternative thrombolytic agent that might be preferred over alteplas
86 yocardial infarction less commonly receive a thrombolytic agent, use of thrombolytic therapy in this
87 oup analyses to assess the effect of type of thrombolytic agent used and the strategy of emergent hos
88 up, and were independent of both the type of thrombolytic agent used, and whether or not the patient
89 association between age and treatment with a thrombolytic agent was determined by crude and multivari
90 We demonstrated that long-term exposure to a thrombolytic agent was essential to achieve high thrombo
91                                     Use of a thrombolytic agent was inversely related to patient age:
92                However, the interaction with thrombolytic agents was not specifically assessed.
93 ocardial infarction, the odds of receiving a thrombolytic agent were significantly reduced for patien
94 ngiotensin-converting enzyme inhibitors, and thrombolytic agents were used in 72%, 39%, 32%, and 15%
95 olysis, but the relative benefits of various thrombolytic agents with earlier administration are unce
96               Over the past two decades, new thrombolytic agents with sufficient pharmacologic potenc